Inhibitex LLC  

(Public, NASDAQ:INHX)   Watch this stock  
Find more results for INHX
0.0000
Real-time:  
NASDAQ real-time data - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 2.04B
P/E     -
Div/yield     -
EPS -0.37
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '11) 2010
Net profit margin -417.94% -1217.68%
Operating margin -419.94% -1248.27%
EBITD margin - -1214.38%
Return on average assets -36.53% -73.18%
Return on average equity -40.93% -93.31%
Employees 33 -
CDP Score - -

Address

9005 Westside Parkway
ALPHARETTA, GA 30009
United States - Map
+1-678-7461100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Inhibitex, Inc. develops antibody-based products for the treatment and prevention of bacterial and fungal infections. The Company produces products that can be used as vaccines, binding inhibitors or separation supports for affinity purifications. The Company's lead product candidate, Veronate, which entered into Phase III clinical trial in the second half of 2004, is being developed for the prevention of hospital-associated infections in premature, very low birth weight, (VLBW) infants.